Elicio Therapeutics and Angion enter into merger agreement to advance cancer vaccine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login